A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma
A partir d'une revue de la littérature, cette étude évalue l'efficacité de la trabectédine pour traiter les patients atteints d'un liposarcome myxoïde de stade avancé
Myxoid liposarcoma (MPLS) is a rare mesenchymal tumor that constitutes 10-20% of all liposarcomas. MPLS is a translocation-related sarcoma (TRS) related to the chromosomal translocation t(12:16) (q13:p11), producing the FUS-CHOP oncoprotein that constitute one of the main targets of trabectedin in MPLS patients. It is known to be chemosensitive namely to trabectedin in contrast to other soft tissue sarcomas. The efficacy of this agent in MPLS have been demonstrated in different settings including treatment-naïve and pre-treated patients with both locally advanced and metastatic disease. However, the benefits of trabectedin in MPLS are shadowed by the limited activity of this drug in other subtypes of sarcomas that are enrolled within the same trials. The efficacy of trabectedin This prompted us to screen the medical literature for clinical data that evaluates the efficacy and safety of trabectedin in MPLS. In this review, we will summarize the available evidence for the applicability of trabectedin in MPLS.